Total de visites
| Visites | |
|---|---|
| VHIO ... | 2264 |
Total de visites per mes
| de maig 2025 | de juny 2025 | de juliol 2025 | d’agost 2025 | de setembre 2025 | d’octubre 2025 | de novembre 2025 | |
|---|---|---|---|---|---|---|---|
| VHIO ... | 27 | 17 | 37 | 67 | 359 | 28 | 715 |
Visites per país
| Visites | |
|---|---|
| Estats Units | 1214 |
| Espanya | 776 |
| França | 51 |
| Singapur | 27 |
| Rússia | 22 |
| Suècia | 19 |
| Brasil | 16 |
| Irlanda | 15 |
| Xina | 11 |
| Regne Unit | 9 |
Visites per ciutat
| Visites | |
|---|---|
| Barcelona | 439 |
| Dallas | 417 |
| Buffalo | 290 |
| Los Angeles | 229 |
| Capellades | 60 |
| Tarragona | 37 |
| Ashburn | 32 |
| Sabadell | 20 |
| Singapore | 19 |
| Dublin | 15 |
Documents més visitats
| Visites | |
|---|---|
| GWAS-Identified Variants for Obesity Do Not Influence the Risk of Developing Multiple Myeloma: A Population-Based Study and Meta-Analysis | 991 |
| Cancer Core Europe: A translational research infrastructure for a European mission on cancer | 947 |
| Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer | 944 |
| Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study | 904 |
| FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer | 834 |
| Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC | 792 |
| Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival | 773 |
| Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity | 704 |
| 1H NMR serum metabolomic profiling of patients at risk of cardiovascular diseases performing stress test | 669 |
| 2023 GEIS Guidelines for gastrointestinal stromal tumors | 645 |



